Stempeutics Research, a part of the Manipal Education and Medical Group (MEMG), has received process patent from the State Intellectual Property Office of China (SIPO) for its novel stem-cell based drug Stempeucel for the treatment of Critical Limb Ischemia (CLI), a progressive form of peripheral arterial disease.
Critical limb ischaemia (CLI) is a manifestation of peripheral arterial disease (PAD) that describes patients with chronic ischaemic rest pain, or patients with ischaemic skin lesions, either ulcers or gangrene. About 20 per cent of elderly urban Chinese suffer from peripheral arterial disease (PAD) and the prevalence in women is substantially higher than in men. CLI is a progressive form of PAD and smokers are at high risk of contracting PAD.
Stempeutics has already submitted its application to the Drug Controller General of India (DCGI) to obtain marketing authorisation approval for Stempeucel. The availability of the product in the market is subjected to DCGI approval. Stempeutics which was set up in 2006 entered into a strategic alliance with Cipla in 2009.
Subscribe to PharmaTutor News Alerts by Email >>
